Updates on cardiovascular outcome trials in diabetes

In 2008 the Food and Drug Administration introduced a guidance for industry that requires the investigation of cardiovascular outcomes of glucose-lowering medications. Since then, an increasing number of cardiovascular outcome trials have been completed in diabetes patients with high cardiovascular...

Descripción completa

Detalles Bibliográficos
Autores principales: Schnell, Oliver, Rydén, Lars, Standl, Eberhard, Ceriello, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5637292/
https://www.ncbi.nlm.nih.gov/pubmed/29020969
http://dx.doi.org/10.1186/s12933-017-0610-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5637292/
https://www.ncbi.nlm.nih.gov/pubmed/29020969
http://dx.doi.org/10.1186/s12933-017-0610-y

Ejemplares similares